NCT01003028View on ClinicalTrials.gov

Reduction of Remifentanil-related Complications

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2026

Conditions
Anesthesia
Interventions
DRUG

Remifentanil (Limited) - Target Controlled Infusion system

Limit max plasma concentration to 9.8 ng/ml

DRUG

Remifentanil (Control) - Target Controlled Infusion system

Use 20 ng/ml as max plasma concentration

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT01003028 - Reduction of Remifentanil-related Complications | Biotech Hunter | Biotech Hunter